News coverage about Sunshine Heart (NASDAQ:CHFS) has trended somewhat positive this week, according to Accern. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Sunshine Heart earned a news sentiment score of 0.02 on Accern’s scale. Accern also assigned media stories about the company an impact score of 46.0591308853816 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the news articles that may have impacted Accern Sentiment’s scoring:
- Christine Lynne Carpenter Billman, 58 (titusvilleherald.com)
- We all have everyday heroes — Here’s how mine changed my life (foxnews.com)
- Zacks: Sunshine Heart Inc (CHFS) Given $15.00 Average Price Target by Brokerages (americanbankingnews.com)
- Warhol for All (palmspringslife.com)
- Senate Continues Looking for a Gambling Deal (sunshinestatenews.com)
Shares of Sunshine Heart (CHFS) traded up $0.12 during midday trading on Tuesday, reaching $3.17. The company’s stock had a trading volume of 138,700 shares, compared to its average volume of 563,159. The stock has a market capitalization of $5.70, a price-to-earnings ratio of -0.02 and a beta of 2.34. Sunshine Heart has a 52 week low of $2.87 and a 52 week high of $101.80.
About Sunshine Heart
CHF Solutions, Inc, an early-stage medical device company, develops cardiac and coronary disease products primarily in the United States. It focused on commercializing the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.
Receive News & Ratings for Sunshine Heart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Heart and related companies with MarketBeat.com's FREE daily email newsletter.